Overview

Vitamin D and Hereditary Haemorrhagic Telangiectasia

Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The study aims to assess whether supplementing vitamin D in patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT) will decrease the frequency and severity of nosebleeds these patients experience. It is hypothesized that the larger the dose of daily vitamin D given to the patients, the less frequent and less severe the nosebleeds will be.
Phase:
Phase 2
Details
Lead Sponsor:
St. Paul's Hospital, Canada
Treatments:
Ergocalciferols
Vitamin D
Vitamins